The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016:

• 37 negotiations are currently underway with no new files added since the last update of August 31, 2016.

• 118 joint negotiations have been completed with 4 files successfully negotiated since the last update of August 31, 2016:
  • Esbriet (pirfenidone): used to treat idiopathic pulmonary fibrosis (second letter of intent)
  • Ferriprox (deferiprone): used to treat Transfusional Iron Overload
  • Ofev (nintedanib): used to treat idiopathic pulmonary fibrosis
  • Revlimid (lenalidomide): used to treat newly diagnosed multiple myeloma (second letter of intent

• 38 drug products for which the pCPA has decided not to negotiate collectively or individually at the  provincial-territorial level with no new files added since the last update of August 31, 2016.

• 13 negotiations for brand name drug products have been recommended by the pCPA to be  considered by each Province/Territory individually with no new files added since the last update of August 31, 2016.

For more information, please consult the pCPA’s website.